Early Detection of Ovarian Cancer by Molecular Targeted Ultrasound Imaging Together with Serum Markers of Tumor-Associated Nuclear Change and Angiogenesis
Abstract
One of the most significant barriers to establishing an early ovarian cancer (OVCA) detection test is the difficulty of identifying patients with early stage OVCA. In earlier approaches to develop an early detection test for OVCA, using serum levels of CA- 125, traditional transvaginal ultrasound and their combination did not improve the detection of OVCA remarkably. The limitation of CA-125 is that it is non-specific in detecting OVCA at the early stage and no imaging target(s) in the ovary corresponding to the elevated serum CA-125 levels has been defined. Our overall goal is to establish an early detection test for OVCA using vascular endothelial growth factor receptor -2 (VEGFR-2) targeted ultrasound molecular imaging in association with serum anti-nuclear matrix protein (anti-NMP) antibodies (a marker of tumor associated nuclear change) and serum IL-16 levels (a marker of ovarian tumor-associated neoangiogenesis, TAN). This goal is being achieved by two specific aims. The results of Aim 1 suggest that VEGFR-2 targeted ultrasound imaging enhances the detection of ovarian tumors in the laying hen model of spontaneous OVCA. Changes in OVCA related VEGFR-2 targeted imaging indices are associated with the prevalence of serum anti-NMP antibodies and the elevation of serum IL-16 levels.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA569445
Entities
People
- Animesh Barua
Organizations
- Rush University